Faculty Opinions recommendation of Recognizing the Leaky Gut as a Trans-diagnostic Target for Neuroimmune Disorders Using Clinical Chemistry and Molecular Immunology Assays.

Author(s):  
Alessio Fasano
2018 ◽  
Vol 18 (19) ◽  
pp. 1641-1655 ◽  
Author(s):  
Denitsa Simeonova ◽  
Mariya Ivanovska ◽  
Mariana Murdjeva ◽  
Andre F. Carvalho ◽  
Michael Maes

Background: Increased intestinal permeability with heightened translocation of Gramnegative bacteria, also known as “leaky gut”, is associated with the pathophysiology of neuroimmune disorders, such as Major Depressive Disorder (MDD), Chronic Fatigue Syndrome (CSF) and (deficit) schizophrenia, as well as with general medical disorders, including irritable bowel syndrome. This review aims to summarize clinical biochemistry and molecular immunology tests that may aid in the recognition of leaky gut in clinical practice. <p> Methods: We searched online libraries, including PubMed/MEDLINE, Google Scholar and Scopus, with the key words “diagnosis” or “biomarkers” and “leaky gut”, “bacterial translocation”, and “intestinal permeability” and focused on papers describing tests that may aid in the clinical recognition of leaky gut. <p> Results: To evaluate tight junction barrier integrity, serum IgG/IgA/IgM responses to occludin and zonulin and IgA responses to actomyosin should be evaluated. The presence of cytotoxic bacterial products in serum can be evaluated using IgA/IgM responses to sonicated samples of common Gram-negative gut commensal bacteria and assays of serum lipopolysaccharides (LPSs) and other bacterial toxins, including cytolethal distenting toxin, subunit B. Major factors associated with increased gut permeability, including gut dysbiosis and yeast overgrowth, use of NSAIDs and alcohol, food hypersensitivities (IgE-mediated), food intolerances (IgG-mediated), small bacterial overgrowth (SIBO), systemic inflammation, psychosocial stressors, some infections (e.g., HIV) and dietary patterns, should be assessed. Stool samples can be used to assay gut dysbiosis, gut inflammation and decreased mucosal defenses using assays of fecal growth of bacteria, yeast and fungi and stool assays of calprotectin, secretory IgA, β-defensin, α- antitrypsin, lysozyme and lactoferrin. Blood and breath tests should be used to exclude common causes of increased gut permeability, namely, food hypersensitivities and intolerances, SIBO, lactose intolerance and fructose malabsorption. <p> Discussion: Here, we propose strategies to recognize “leaky gut” in a clinical setting using the most adequate clinical chemistry and molecular immunology assays.


2011 ◽  
Vol 44 (16) ◽  
pp. 29
Author(s):  
MICHELE G. SULLIVAN
Keyword(s):  

2019 ◽  
Vol 13 (04) ◽  
pp. 190-196
Author(s):  
Lucas Massier ◽  
Peter Kovacs
Keyword(s):  

ZusammenfassungDurch die Veränderung der intestinalen Permeabilität können Faktoren wie das Mikrobiom, Ernährung oder Medikamentengabe Einfluss auf die Entwicklung von Parametern des metabolischen Syndroms nehmen. Dabei kommt es zu Veränderungen im parazellulären Raum, durch die ein Influx von bakteriellen Bestandteilen möglich wird. Adipositas und Diabetes sind zudem mit erhöhten Endotoxinspiegeln in der von Endotoxin, z. B. über den TLR4 Rezeptor bekannt sind, ist der genaue Beitrag zu Merkmalen des metabolischen Syndroms noch unklar. Klar ist aber, dass Entzündung und Insulinresistenz erhöht werden können. Auch die Frage nach einem „Gewebs“-Mikrobiom im metabolischen Syndrom kann aufgrund der Datenlage noch nicht eindeutig beantwortet werden, denn obwohl erste Daten bakterielle DNA im Fettgewebe zeigen, gibt es auch gegensätzliche Arbeiten. Ein „Leaky Gut“ ist ein mögliches Merkmal des metabolischen Syndroms, welches zu den beobachteten Phänotypen beiträgt und, u. a. durch die erhöhte Entzündung in einem negativen Feedbackloop die intestinale Permeabilität weiter erhöhen kann.


2014 ◽  
Vol 3 (2) ◽  
pp. 153
Author(s):  
P Swathi ◽  
M Prasanth ◽  
MM Suchitra ◽  
AparnaR Bitla

2020 ◽  
Vol 0 (3) ◽  
pp. 91-95
Author(s):  
V. V. Chernyavskyi ◽  
L. L. Pavlovskyi ◽  
V. V. Tishchenko
Keyword(s):  

2020 ◽  
Vol 20 ◽  
Author(s):  
Suman K Ray ◽  
Yamini Meshram ◽  
Sukhes Mukherjee

: Cancer immunotherapy endeavours in harnessing delicate strength and specificity of immune system for therapy of different malignancies including colorectal carcinoma. The recent challenge for cancer immunotherapy is to practice and develop molecular immunology tools to create tactics that efficiently and securely boost antitumor reactions. After several attempts of deceptive outcomes, the wave has lastly altered and immunotherapy has become a clinically confirmed treatment for several cancers. Immunotherapeutic methods include administration of antibodies or modified proteins that either block cellular activity or co-stimulate cells through immune control pathways, cancer vaccines, oncolytic bacteria, ex vivo activated adoptive transfer of T cells and natural killer cells. Engineered T cells are used to produce a chimeric antigen receptor (CAR) to treat different malignancies including colorectal carcinoma in a recent decade. Despite considerable early clinical success, CAR-T therapies are associated with some side effects and sometimes display minimal efficacy. It gives special emphasis on the latest clinical evidence with CAR-T technology and also other related immunotherapeutic methods with promising performance, and highlighted how this therapy can affect therapeutic outcome and next upsurge as a key clinical aspect of colorectal carcinoma. In this review we recapitulate the current developments produced to improve the efficacy and specificity of CAR-T therapies in colon cancer.


Sign in / Sign up

Export Citation Format

Share Document